A shot at migraine

See allHide authors and affiliations

Science  08 Jan 2016:
Vol. 351, Issue 6269, pp. 116-119
DOI: 10.1126/science.351.6269.116

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Millions dread the onset of migraine headaches, which strike roughly 12% of the world's population at least once per year. Existing treatments can only head off migraines after they start, and don't work for many people. On the horizon, however, is a new class of drugs that many scientists believe can stop migraines at their root. Four pharmaceutical companies are racing to complete advanced clinical trials of antibody drugs that block the activity of a molecule called calcitonin gene-related peptide, or CGRP, which spikes during migraine attacks. The discovery of CGRP may also help to solve the centuries-old puzzle of what triggers a migraine's complex neurological events.